Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTULV0X)

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tafenoquine	DM1XT4N	Malaria	1F40-1F45	Approved	[1]
------------------------------------------------------------------------------------

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mitoquinone	DMKPZ0Q	Hepatitis C virus infection	1E51.1	Phase 2	[2]
Procysteine	DMF9RB4	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[3]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[4]
------------------------------------------------------------------------------------

References

1	Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523.
2	Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192.
3	Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions. J Antimicrob Chemother. 2013 Oct;68(10):2305-10.
4	A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35.